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Objective To estimate the cost-effectiveness of a treatment strategy
for symptomatic uterine fibroids, which starts with Magnetic
Resonance-guided Focused Ultrasound Surgery (MRgFUS) as
compared with current practice comprising uterine artery
embolisation, myomectomy and hysterectomy.
Design Cost-utility analysis based on a Markov model.
Setting National Health Service (NHS) Trusts in England and
Wales.
Population Women for whom surgical treatment for uterine
fibroids is being considered.
Methods The parameters of the Markov model of the treatment of
uterine fibroids are drawn from a series of clinical studies of
MRgFUS, and from the clinical effectiveness literature. Health-
related quality of life is measured using the 6D. Costs are estimated
from the perspective of the NHS. The impact of uncertainty
is examined using deterministic and probabilistic sensitivity
analysis.
Main outcome measures Incremental cost-effectiveness measured
by cost per quality-adjusted life-year (QALY) gained.
Results The base-case results imply a cost saving and a small
QALY gain per woman as a result of an MRgFUS treatment
strategy. The cost per QALY gained is sensitive to cost of MRgFUS
relative to other treatments, the age of the woman and the
nonperfused volume relative to the total fibroids volume.
Conclusions A treatment strategy for symptomatic uterine fibroids
starting with MRgFUS is likely to be cost-effective.
Keywords Cost-utility analysis, focused ultrasound surgery,
uterine fibroids.
Please cite this paper as: Zowall H, Cairns J, Brewer C, Lamping D, Gedroyc W, Regan L. Cost-effectiveness of magnetic resonance-guided focused ultrasound
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Introduction
Uterine fibroids (leiomyomas or myomas) are benign clonal
tumours of the smooth muscle cells of the uterus.1,2 They are
the most common benign tumours in women during their
reproductive years, with an estimated cumulative incidence of
about 40% for white women aged 35–39, rising to over 60%
in women aged 45–49.3,4 Symptoms attributable to fibroids
can be classified into three categories: abnormal uterine
bleeding, pelvic pressure and pain, and reproductive dysfunc-
tion. Despite the high prevalence, there is considerable debate
and uncertainty about the optimum management of uterine
fibroids. The wide range of treatment options and the lack of
information about natural history, long-term effectiveness,
outcomes and costs can make decision-making difficult for
the women and clinicians.
Studies of outcomes following hysterectomy indicate high
patient satisfaction, improved health-related quality of life
and complete resolution of menstrual disturbance without
the possibility of recurrence. However, hysterectomy is a
major operation that causes considerable disability within 2
months of surgery, has mortality rates in the range of 0.38–1
per 1000, severe complications in 3% of women and minor
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morbidity in up to 30% women.3 Hysterectomy is also
thought to be associated with long-term consequences such
as urinary incontinence years after the operation, which
may cause early ovarian failure, and has significant cost im-
plications. This has stimulated the search for clinically and
cost-effective alternatives to hysterectomy, which provide
comparable quality of life and fewer adverse effects and com-
plications than hysterectomy.3 Established treatments for
uterine fibroids include hysterectomy, myomectomy and
uterine artery embolisation (UAE); endometrial ablative tech-
niques are among emerging new technologies.
MRgFUS uses a noninvasive thermal ablation device inte-
grated with an MR imaging system for the ablation of soft
tissue. Recent applications have included the treatment of
breast, liver, brain and metastatic bone cancers.5–10 The phy-
sician acquires a set of MR images, identifies a target volume
of tissue to be treated and draws the treatment contours.
Therapy planning software calculates the type and number
of sonications required to treat the defined region while min-
imizing total treatment time. During the treatment, a small
bean-shaped volume of focused ultrasound energy is directed
into the target for approximately 15 seconds and heats the
tissue to between 60 and 90C to induce thermal coagulation.
MR images taken during sonication provide a diagnostic
quality image of the target tissue and a quantitative, real-time
temperature map overlay to confirm the therapeutic effect of
the treatment. Typically, 20–50 individual sonications are
delivered over a 2-hour period to complete a treatment.
MRgFUS for uterine fibroids (ExAblate 2000; InSightec,
Haifa, Israel) was approved by the FDA in 2004 (FDA Report,
unpublished). The advantages of MRgFUS over existing ther-
moablative techniques are that it provides continuous MR
imaging of fibroids and adjacent structures such as bowel,
bladder and sacral nerves and provides continuous temper-
ature monitoring to optimize effective tissue coagulation to
prevent injury to adjacent normal tissue.5 The advantages of
MRgFUS over UAE are reduced infection rates and febrile
morbidity, as the thermal coagulated fibroid tissue is easily
absorbed by the body. Overall, MRgFUS is associated with
a low risk of postprocedural complications.
Methods
The aim of this study is to estimate the cost-effectiveness of
a treatment strategy for symptomatic uterine fibroids with
MRgFUS as compared with current practice comprising
UAE, myomectomy and hysterectomy. Results are expressed
as incremental cost-effectiveness ratios (ICERs), specifically
the cost per quality-adjusted life-year (QALY) gained. All
costs and QALYs are discounted at an annual rate of 3.5%.11
At present, decision-making regarding fibroids can be dif-
ficult primarily due to a paucity of data regarding natural
history, effectiveness of available treatments and associated
costs. Decision modelling provides a concise and explicit
framework to quantify the costs and clinical benefits given
the existing data uncertainty. A Markov model is used to
simulate the natural history, to provide projections of possible
outcomes and to identify areas where additional information
is needed to permit informed decisions on the part of pro-
viders, payers and patients. It facilitates inclusion of impor-
tant events, such as progression to further treatment and to
menopause, occurring at different times for different women.
Women are assigned discrete health states simulating the
clinical outcomes, with corresponding costs and quality of life,
and move from one health state to another over time according
to preselected transition probabilities. The structure of the
model where treatment starts with MRgFUS is presented in
Figure 1. Current practice is represented by the same model
with MRgFUS omitted. Following an initial fibroid treatment,
women can recover from the procedure, with or without short
and long-term complications, or die due to the procedure.
Those who recover, with or without complications, and
require further treatment are classified as failures. Women
who do not require further treatment to alleviate fibroid-
related symptoms are classified as successes. Treatments can
be ordered in terms of increasing invasiveness (MRgFUS, UAE,
myomectomy, hysterectomy). Women who fail with their ini-
tial treatment proceed over time to a more invasive procedure.
In the base case, the model starts at age 39 and follows
women until age 56. There are assumed to be no clinical or
cost differences between treatments after menopause. In the
absence of UK data on the proportion of women receiving
UAE, myomectomy or hysterectomy as their initial treatment
for uterine fibroids, it is assumed in the base case that women
are distributed across the three treatments, 25% to UAE, 25%
to myomectomy and 50% to hysterectomy. All outcomes,
except quality of life, are tracked in cycles: for the initial
procedures over 6 and 12 months, and yearly thereafter. Qual-
ity-of-life estimates are calculated monthly within the first
year following procedure and annually thereafter. Women
are followed individually for all possible events and only
one event can occur per cycle. At the end of each cycle, the
woman may either become menopausal or die of other causes
unrelated to fibroids. Age-specific death rates from causes
other than procedural death are taken from UK Life Tables.12
Transition probabilities following MRgFUS were estimated
by modelling the relationship between nonperfused volume
(NPV) relative to the total fibroids volume and the rate of
alternative treatment. NPV is the volume of tissue that does
not enhance on contrast MRI following administration of
a MR contrast agent. The NPV ratio is a surrogate measure
of treatment success. Higher NPV ratios are associated with
lower probabilities of recurrence due to fibroid regrowth and
a reduced need for additional procedures. Data from
InSightec clinical studies (clinical studies included: UF002
(109 participants); UF005 (160 participants); and UF014
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(73 participants)) were pooled and separate logistic regres-
sions were estimated for 342 women followed over the first 6
months, 248 women followed over the 6–12-month period
with no previous alternative treatment and 143 women fol-
lowed over the 12–24-month period with no previous alter-
native treatment. Comparison of the observed and the
predicted rates of alternative treatment for different NPV
ratios indicates that there is no systematic over- or under-
prediction by these models.
Progression rates beyond the available data were modelled
assuming a constant rate pegged at the 24-month data for
a predetermined number of years. Some studies suggest that
recurrence occurs only in the first 4 years after initial treat-
ment and that women do not seek additional treatments
thereafter.13 The transitional probabilities of recurrence from
UAE and myomectomy to additional procedures over time
were obtained from the literature (references in Table 1).
An NPV ratio of 60% has been assumed in the base case
reflecting current commercial practice (Insightec internal
data). Based on the logistic regression analysis, for a NPV
ratio of 60%, the recurrence rate following MRgFUS is
0.80% for the 0–6-month follow-up period, 6.49% for the
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Figure 1. Structure of the model.
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6–12-month follow-up period and 3.63% for the 12–24-month
follow-up period. This compares to a cumulative 5-year recur-
rence rate of 62% following myomectomy.23 The percentage
distribution of alternative treatments following MRgFUS
among UAE, myomectomy and hysterectomy was taken from
the UF005-B2 database. According to current commercial pro-
tocols, if needed, the MRgFUS treatment can include a second
MRgFUS session within 2 weeks of the initial treatment. Based
on the NPV database, 3.88% of the women from the clinical
studies have undergone a second MRgFUS session.
Data on short- and long-term complications were obtained
from the UF0025,6 and UF005 studies.24 To date, over 3000
women worldwide have been treated with MRgFUS. Safety data
from these studies consistently show that there are no FDA
reportable adverse events related to MRgFUS. The only
device-related adverse events reported include skin burns and
nerve damage following MRgFUS, which resolved within a
year.25 There were no emergency surgical interventions required
after MRgFUS. No unexpected short-term adverse events and
no long-term complications have been observed to date. Data
on outcomes, including procedural death, short- and long-term
complications, recurrence rate of alternative treatments and
quality of life were taken from the literature (Table 1).
Health-related quality of life following successful treatment
is assumed to be the same for MRgFUS and other treatments.
This assumption is consistent with the results of recent studies
comparing quality of life following hysterectomy versus med-
ical treatment.26–28 A health state utility of 0.802 was observed
at 6 months in the UF002 study. This was derived by convert-
ing Short Form(SF)-36 data to the SF-6D.29 Quality of life is
assumed not to change beyond 6 months post-treatment
(based on the absence of any statistically significant improve-
ments in quality of life at 12 and 24 months (in UF008).7
This is consistent with Sculpher et al. who reported little
change in health-related quality of life between 4 months
and 1 year after hysterectomy.30 Utility following treatment
with MRgFUS is 0.783 (based on UF002). Similar utility is
assumed following UAE. Utility following hysterectomy (and
myomectomy) is assumed to be 0.757 applying the change in
utility observed in Garside et al.17 and assuming that utility at
6 months following successful treatment is 0.802. Quality of
life among failures is assumed not to change. Reductions in
quality of life due to complications have been estimated from
the literature.15–17
This study assumes an National Health Service (NHS) per-
spective. Costs to the NHS include initial and subsequent
Table 1. Parameter values assumed in base case
Hysterectomy Myomectomy UAE MRgFUS
Procedure-related death % 0.03813 0* 0.021,3 0a,c,d
Major complications at 1 year
% 6.214 6.2* 3.9215 0*
Cost £2,28219–22 £2,282* £2,282*
Minor complications at 1 year
% 27.114 27.1* 20.615 0a,b,d
Cost £29319–22 £293* £293*
Long-term complications 6.214 6.2* 3.9215
Duration 2 yrs* 1 year* 1 year*
Cost £61819–22 £0* £0*
Cost of outpatient monitoring
Year 1 £15219–22 £152* £39819 £39819
Subsequent years £0* £0* £0* £0*
Hospital cost £272719 £2727* £2727* £2000f
Annual probability of subsequent hysterectomy 0.033417 0.030318
Annual probability of subsequent myomectomy 0.009718
Utility post-treatment 0.75716 0.757* 0.783* 0.783a
Utility fully recovered or post-menopausal 0.802* 0.802* 0.802* 0.802a
% Repeat MRgFUS within 2 weeks 3.88a,b,c,e
0–6 months 6–12 months 12–24 months After 24 months
% Further treatment (NPV: 60%) 0.80a,b,c,e 6.49a,b,c,e 3.63a,b,c,e 3.63*
% UAE 0.20a,b,c,e 2.16a,b,c,e 1.82a,b,c,e 1.82*
% Myomectomy 0a,b,c,e 2.16a,b,c,e 0a,b,c,e 0*
% Hysterectomy 0.60a,b,c,e 2.16a,b,c,e 1.82a,b,c,e 1.82*
Key: numeral (see references); *Assumption; a, UF002; b, UF003; c, UF005; d, UF008; e, UF014; f, St Mary’s NHS Trust (adjusted for MFF).
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hospitalisations and outpatient services such as day proce-
dures, diagnostic tests, medical personnel, medication costs
etc. Since all symptomatic women routinely undergo pre-
treatment evaluations before being offered any treatment,
these costs are not included in the comparison between treat-
ment strategies.
Hospital costs of MRgFUS are based on estimates of
resource use obtained from St Mary’s NHS Trust, London
including all personnel costs, medical consumables, MR time,
equipment and maintenance costs. Because some of the costs
are independent of the number of women treated, the cost per
woman is sensitive to assumptions regarding the number of
women treated. In the base case it is assumed that 220 women
are treated annually (on average five women per week for 44
weeks in each year). At this level of patient throughput the
estimated cost is £2382 per woman. Such costs are, however,
unrepresentative of what the cost of MRgFUS would be else-
where in the UK. The Department of Health recognizes that
providers operating in areas such as London and the South
East face higher costs for staff, land and buildings due to
external market forces.20 To compensate for this, the Market
Forces Factor (MFF) adjustment is employed and the MFF for
St Mary’s NHS Trust is the highest in the country. Accord-
ingly, all costs (other than consumables and equipment costs)
have been multiplied by 0.78 (the ratio of the mean MFF for
all English NHS Trusts to the MFF for St Mary’s). The esti-
mated cost of MRgFUS of £2000 is more comparable to the
National Reference Costs for other procedures.
The mean cost of elective inpatient hysterectomy is £2727,
with an interquartile range of £2054 and £3157.20 Since the
literature indicates that there is little variability in the initial
hospital costs between UAE, myomectomy and hysterec-
tomy31,32 the cost of all three is assumed to be £2727. Out-
patient medical costs were derived using the 2005 NHS
Reference Costs and the 2004 Personal Social Services Re-
search Unit.20,21 Outpatient medication costs were obtained
from the British National Formulary and the Scottish Pre-
scription Cost Analysis.22,33
The effect of uncertainty in the parameters of the model
(such as the definition of current practice, the NPV ratio, age
of the woman, procedural deaths, recurrence rates, complica-
tions rates, quality of life and treatment costs) were studied
using extensive one-way and two-way sensitivity analyses.
Probabilistic simulations were carried out to account for
the effect of uncertainty regarding the model inputs on cost-
effectiveness. To do this, 20 000 simulations were generated,
simultaneously varying the following parameters for all four
procedures: recurrence rates, complications rates, procedural
death, quality of life and hospital costs. Values for the tran-
sitional probabilities and health state utilities were sampled
from a beta distribution. The distribution of costs for hyster-
ectomy, myomectomy and UAE was assumed to be log-
normal with 0.005 and 99.995% quantiles of £1933 and
£3818 (140% of its assumed mean of £2727). The log-normal
distribution for cost of MRgFUS was chosen so that the
99.995% quantile was also 140% of its assumed mean
(£2000). The resulting 20 000 ICERs indicate the range of
outcomes that might be expected given the inherent uncer-
tainty in the underlying data. These data are then used to
generate a cost-effectiveness acceptability curve indicating
the proportion of simulations for which a particular interven-
tion has a positive net benefit (i.e. it shows the probability that
the MRgFUS strategy is cost-effective for different willing-
nesses-to-pay for a QALY).
All analyses were performed using Microsoft Office Excel
2003 software.
Results
The results of the base-case scenario are presented in Table 2.
The total discounted direct medical costs of 1000 women
treated with MRgFUS at age 39 and followed until menopause
or age 56 have been estimated at £3,101,644, compared with the
cost of £3,396,913 for 1000 women treated with currently avail-
able procedures. Thus, the incremental cost of an MRgFUS
treatment strategy compared with current treatment, results in
a cost saving of £295,269. Moreover, MRgFUS treatment com-
pared with current practice increased total QALYs by 10.658. In
the base case, MRgFUS is dominant, that is, has a lower cost
and better outcomes than the existing treatment strategy
(although the QALY difference per woman is very small).
The results of the deterministic sensitivity analysis are sum-
marized in Table 2, scenarios 2–13. In scenario 2, the assump-
tion regarding current practice in the UK for the management
of uterine fibroids is changed to UAE (33.33%), myomec-
tomy (33.33%), and hysterectomy (33.33%), rather than the
base-case scenario of 25, 25 and 50%, across the three treat-
ments, respectively. MRgFUS remains the dominant strategy.
Scenarios 3 (and 4) explore more extreme assumptions,
namely that 10% of women (or none) in the current practice
group undergo hysterectomy as their initial treatment (the
remaining women being equally divided between UAE and
myomectomy). MRgFUS remains the dominant strategy.
Indeed the cost savings increase as the proportion undergoing
hysterectomy falls since the costs of UAE and myomectomy
are higher than for hysterectomy once one allows for the
additional treatments required by some women.
In the base case, all successful treatments for uterine fib-
roids are assumed to result in similar improvements in quality
of life after the recovery period; that is, all women after suc-
cessful recovery reach a health state utility value of 0.802
(based on the results for the successfully treated group in
UF002). Although it might be argued that quality of life will
be lower for those women who have had their ovaries
removed. In scenario 5, it is assumed that all women would
reach a health state utility value of 0.95, which is the value for
MRgFUS for treatment of uterine fibroids
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full recovery after hysterectomy, reported by Sculpher et al.34
and used in the Markov model by Garside et al.35 The QALYs
gained as a result of an MRgFUS strategy increase slightly to
12.624 and MRgFUS remains the dominant strategy. Scenario
6 is based on health state utility values used in Hurskainen
et al.,26,27 where utility values for hysterectomy are 0.78 at
baseline and 0.88 at 1 year,27 remaining unchanged at 5 years.26
The QALYs gained as a result of an MRgFUS strategy increase
to 16.292 and MRgFUS remains the dominant strategy.
The impact of alternative assumptions regarding the ef-
fectiveness of the treatments is explored by varying the
assumptions made regarding recurrence rates, NPV ratios,
complication rates and procedural death rates. In scenario
7, the annual recurrence rates of all procedures other than
MRgFUS were decreased by 50%. MRgFUS remains the dom-
inant strategy. When long-term complications for all pro-
cedures are reduced to zero (scenario 8), MRgFUS again
remains the dominant strategy. When the complication rate
for MRgFUS is set equal to that of UAE (scenario 9), MRgFUS
is still the dominant strategy. If procedural death rates for
UAE (0.0002) and hysterectomy (0.00038) are set to zero
(scenario 10), MRgFUS remains the dominant strategy.
The costs of treatment are varied in scenarios 11–13. In
scenario 11 central London (St Mary’s NHS Trust) costs are
assumed for all procedures and MRgFUS remains the
dominant strategy. In scenario 12, the costs of all procedures
(other than MRgFUS) are assumed to be equivalent to the
lower quartile of hysterectomy costs (£2054).20 MRgFUS is no
longer cost saving and the resulting ICER is £27,845 per
QALY. If the initial hospital costs of MRgFUS are increased
from £2000 to £2630 (the estimated cost given three patients
per week), the cost saving is eliminated and the resulting
ICER is £33,685 per QALY (scenario 13).
Predictably, increases in the cost of current treatments or falls
in the cost of MRgFUS, increases in the long-term complication
rates or annual recurrence rates for current procedures, all leave
MRgFUS dominant (with increased estimated cost savings).
A two-way sensitivity analysis varying the cost of MRgFUS
and the costs of alternative treatments at the same time is
presented in Figure 2. The three lines show the combinations
of MRgFUS costs and costs of alternative procedures that
would produce ICERs of £0, £20,000 and £30,000. The close-
ness of these three lines highlights how sensitive results are to
assumptions about the relative cost of MRgFUS and of the
alternative procedures.
In the base case, women were assumed to be aged 39 years.
As the age of women is increased from 35 years to 56 years the
cost saving anticipated as a result of an MRgFUS strategy
increases, and the QALY gain decreases and then becomes
negative. The total QALYs for the successive cohorts fall as
starting age rises for both the MRgFUS and current treatment
strategies. However, the total QALYs for MRgFUS fall faster
than for the current treatment strategy because the predicted
QALY stream in the future is higher for MRgFUS than the
current strategy (as a result of differences in long-term
complications and in procedural mortality). Thus restrictions
Table 2. Base case and deterministic sensitivity analysis
Scenario # MRgFUS Current Practice D Cost (£) D QALY ICER Modified
Model Parameters
Cost (£) QALY Cost (£) QALY
1 3,101,644 10793.874 3,396,913 10783.216 2295,269 10.658 Dominant Base case
2 3,101,644 10793.874 3,486,202 10783.962 2384,558 9.912 Dominant Current practice: 33.3% U,
33.3% M, 33.3% H
3 3,101,644 10793.874 3,611,206 10785.005 2509,563 8.868 Dominant Current practice: 45% U, 45% M, 10% H
4 3,101,644 10793.874 3,664,780 10785.453 2563,136 8.421 Dominant Current practice: 50% U, 50% M, 0% H
5 3,101,644 12785.761 3,396,913 12773.136 2295,269 12.624 Dominant Utility following successful treatment 0.95
6 3,101,644 11853.732 3,396,913 11837.439 2295,269 16.292 Dominant Utility following HYS 0.78 rising
to 0.88 at 1 year
7 3,077,224 10794.263 3,279,248 10785.032 2202,023 9.231 Dominant Recurrence rate for HYS, UAE
& MYO halved
8 3,074,941 10794.140 3,242,757 10785.871 2167,816 8.270 Dominant Zero long-term complications for
all procedures
9 3,101,644 10793.509 3,396,913 10783.216 2295,269 10.293 Dominant MRgFUS complications equal to UAE
10 3,101,675 10794.366 3,397,053 10786.049 2295,378 8.317 Dominant Zero procedural deaths with HYS and UAE
11 3,650,212 10793.874 4,320,922 10783.216 2670,710 10.658 Dominant Hospital costs £2382 for MRgFUS, £3151 for
UAE, £3715 for MYO & HYS
(Central London)
12 2,968,182 10793.874 2,671,423 10783.216 296,759 10.658 £27,845 Hospital costs £2054 for UAE, MYO & HYS
13 3,755,912 10793.874 3,396,913 10783.216 359,000 10.658 £33,685 Hospital costs £2630 for MRgFUS
(3 patients per week)
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in the time horizon causes more QALYs to be lost from the
MRgFUS strategy compared with the current treatment strat-
egy. Up until age 43, MRgFUS is the dominant strategy. For
women aged 44 and above MRgFUS is associated with a loss
of QALYs compared with current practice, although MRgFUS
remains cost saving. At age 44 the ICER for the current treat-
ment strategy over MRgFUS is £79,863; at age 45 it is £78,677
per QALY. Whereas, at ages 46 and 47 the ICER for the
current strategy falls to £23,659 and £21,739. Current treat-
ment is cost-effective for women aged 48 and over.
As the NPV ratio rises, a predicted QALY loss with MRgFUS
becomes a predicted QALY gain with no difference in the
number of QALYs arising between 25 and 30%. MRgFUS
has a positive net cost, which decreases as the NPV ratio
increases, and it becomes cost saving between an NPV ratio
of 45 and 50%. Thus, up to 25%, MRgFUS is dominated by
current practice. Between 30 and 45% MRgFUS produces
additional QALYs with a cost per QALY of £304,850 at
30%, and £5040 at 45%. NPV values of 50% and above result
in MRgFUS being the dominant strategy with rising positive
incremental QALYs and increasing cost savings.
Probabilistic simulations were undertaken to account
for the effect of uncertainty in the model inputs on cost-
effectiveness; 20,000 simulations were performed, simulta-
neously varying the following parameters for all four proce-
dures: procedural death, recurrence rates, complications
rates, quality of life and treatment cost. The results of the
probabilistic sensitivity analysis are presented in Figure 3.
For approximately 86% of simulations, MRgFUS is dominant
(positive incremental QALYs and negative incremental costs).
The median solution results in incremental QALYs of 10.173
and cost savings of £285,684.
Discussion
A treatment strategy for symptomatic uterine fibroids starting
with MRgFUS is likely to be cost-effective. In the base case it is
dominant, that is, it has a lower cost and better outcomes than
the current treatment strategy—on average a cost saving of
about £295 and a gain of one hundredth of a QALY per
woman. It remains cost-effective under alternative assump-
tions regarding current practice, health utility estimates
before and after treatment and the effectiveness of alternative
treatments (complication rates, recurrence rates and proce-
dural death rates).
The cost per QALY gained is sensitive to the cost of
MRgFUS relative to other treatments, the age of the woman
and the NPV relative to the total fibroids volume. For
example, if the lower quartile costs for hysterectomy are
assumed or if three women per week (rather than five)
undergo MRgFUS, MRgFUS has a cost per QALY gained
close to £30,000 rather than being the dominant strategy.
MRgFUS is cost-effective up until the age of 45. At ages 46
and 47 the current strategy produces additional QALYs at
an incremental cost, which might be viewed as acceptable.
However, if a cost-effectiveness threshold of £20,000 per
QALY is applied, MRgFUS would be considered the cost-
effective treatment strategy.11 Finally, the results are sensi-
tive to the NPV ratio achieved by MRgFUS, MRgFUS
becomes cost-effective between 40 and 45% and dominant
above 50%.
The probabilistic simulations show the range of outcomes
that might be expected in practice, given the underlying
uncertainty in available data. The finding that MRgFUS is
dominant in approximately 86% of simulations provides
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Figure 2. Two-way sensitivity analysis—cost of MRgFUS versus cost of alternative treatment.
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strong support for its cost-effectiveness. The probabilistic
sensitivity analysis confirms the results of the deterministic
sensitivity analysis. These results should be treated with
appropriate caution recognising, in particular, the limitations
of the available cost data.
This is the first study to evaluate the cost-effectiveness of
adding MRgFUS technology to the arsenal of existing treat-
ments for uterine fibroids. Data from the available studies of
MRgFUS are combined with extensive sensitivity analyses to
handle the inevitable uncertainty in the available data. More-
over, all model parameters regarding UAE, myomectomy and
hysterectomy are based on recent literature (post-1999).
Despite providing extensive sensitivity analyses, there
remains some inherent uncertainty regarding the model’s
parameters. The model, by necessity, depends on inferred
comparisons in the absence of data from RCTs involving
head-to-head comparisons of MRgFUS versus current treat-
ments. Such inferred comparisons are subject to bias and con-
founding and should be viewed with caution. However, in the
absence of direct head-to-head comparisons, such analyses are
the only suitable approach for assessing cost-effectiveness.
Given the frequency of the tumour and its role in the inci-
dence of hysterectomy, it is remarkable that there have been
so few RCTs comparing hysterectomy to other treatment
modalities for fibroids.3 In a systematic review of 1084 studies
on the surgical and nonsurgical management of fibroids in
2002,36 the authors were unable to perform meta-analysis
because of the lack of consistent data on many important
preclinical variables and the use of different outcome meas-
ures across studies. In 2006, the Cochrane Library produced
a systematic review of the clinical effectiveness of UAE versus
hysterectomy and myomectomy based on the results of
RCTs.37 The review showed a reduction in length of hospital
stay and quicker resumption to daily activities with UAE.
Patient satisfaction is similar between UAE and surgery (hys-
terectomy and myomectomy). Similar findings have been
reported in a recent trial.38 There is the suggestion that
UAE is associated with more intraprocedure and postproce-
dure complications. Thus, UAE results in high rates of failure
and the need for additional interventions. The authors con-
cluded that there is a continued need for further research
involving larger RCTs and longer follow up.
A US Technology Assessment Evidence Report in 200039
concluded that there is almost no high-quality evidence to
reach definitive conclusions regarding the management of
uterine fibroids. The fact that there is so little evidence for
women, clinicians and policy makers to use in making deci-
sions about the management of such a common condition is
striking. They called for future research to improve compa-
rability across studies, to provide data on long-term outcomes
and the use and costs of healthcare services in order to estab-
lish cost-effectiveness baselines.
This study has not taken account of the reproductive impli-
cations of available treatments; the results of the model apply
only to women with no desire for future pregnancy. Many
women are concerned about preserving their fertility, and
decision-making is greatly influenced by this concern; in
many cases they may postpone treatment until later in life.
However, MRgFUS is believed to be the treatment, which
offers a way to preserve fertility.40–42 If this is the case, there
may be additional quality of life gains associated with
MRgFUS that were not captured in this study. Thus, inclusion
of fertility consequences on quality of life might improve the
overall cost-effectiveness of MRgFUS.
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Also an NHS perspective has been adopted, had the loss of
productivity also been taken into account this would further
strengthen thecase for a strategy starting with MRgFUS as a result
of the cohort experiencing fewer hysterectomies. Valuing time
off work using average earnings increases the cost savings from
the MRgFUS strategy by more than £500 per woman.
Despite the paucity of data, decisions regarding resource
allocation in health care have to be made. A requirement of
many regulatory bodies, including those in the UK, is the need
to demonstrate the value of a new intervention through a cost-
effectiveness analysis. In the context of limited resources and
ever-expanding need for healthcare services, determining the
value for money of a new intervention is an important consid-
eration for policy makers who have to make choices within
a constrained budget. Thus, clinical effectiveness, costs and
patient preferences must be weighted when assessing value
for money even with imperfect information.43,44
Conclusion
The results of this study support the introduction of MRgFUS
as a treatment for uterine fibroids. A treatment strategy start-
ing with MRgFUS is potentially more effective and less costly
than current practice. However, the degree of uncertainty
attaching to this conclusion, primarily reflecting the quality
of the underlying data, should be emphasised.
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